Intravitreal Voriconazole for the Treatment of Cryptococcus neoformans Endogenous Endophthalmitis Article

Full Text via DOI: 10.31486/toj.19.0043 PMID: 33071668 Web of Science: 000575811500017

Cited authors

  • Haider, Asghar A.; Gallagher, J. R.; Johnson, Jordan S.; Benevento, Joseph D.


  • Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infection. Intravitreal voriconazole has been used for the treatment of fungal endophthalmitis caused by a broad range of fungal pathogens, and a limited number of reports have shown the efficacy of using intravitreal voriconazole for C neoformans endophthalmitis. We report a case of endogenous fungal endophthalmitis caused by C neoformans that was responsive to intravitreal voriconazole.; Case Report: A previously healthy 57-year-old male diagnosed with primary neuroendocrine lung tumor developed endogenous endophthalmitis from C neoformans. The endophthalmitis was resistant to intravenous amphotericin B treatment but was responsive to intravenous fluconazole in one eye and was apparently more responsive to intravitreal voriconazole in the other eye.; Conclusion: Intravitreal voriconazole should be considered for the treatment of cryptococcal endophthalmitis.

Publication date

  • 2020

Published in

International Standard Serial Number (ISSN)

  • 1524-5012

Start page

  • 319

End page

  • 322


  • 20


  • 3